Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, Life Tech, and More

Premium

Title: Methods for Normalizing and for Identifying Small Nucleic Acids

Patent Number: 8,741,569

Filed: Oct. 23, 2009

Lead Inventor: Kai Lao, Applied Biosystems (Life Technologies)


Title: PHD2 Inhibition for Blood Vessel Normalization and Uses Thereof

Patent Number: 8,741,862

Filed: Jan. 20, 2010

Lead Inventor: Peter Carmeliet, Life Science Research Partners


Title: Compositions and Methods for Inhibiting Expression of Transthyretin

Patent Number: 8,741,866

Filed: March 1, 2012

Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals


Title: RNA Sequence-specific Mediators of RNA Interference

Patent Number: 8,742,092

Filed: March 1, 2012

Lead Inventor: Thomas Tuschl, Max Planck Institute


Title: Methods of Novel Therapeutic Candidate Identification through Gene Expression Analysis in Vascular-related Diseases

Patent Number: 8,741,861

Filed: March 27, 2009

Inventor: David Mann, Vascular Biosciences


Title: Panel of microRNAs that Silence the MCL-1 Gene and Sensitize Cancer Cells to ABT-263

Patent Number: 8,742,083

Filed: Dec. 23, 2010

Lead Inventor: Dimitri Semizarov, AbbVie

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.